Role of mitogen-activated protein kinase in cardiac hypertrophy and heart failure

Experimental and Clinical Cardiology

Volumn 8, Issue 4, 2003, Pages 173-183

  Zhang, Weihua ^a   Elimban, Vijayan ^a   Nijjar, Mohinder S ^a   Gupta, Suresh ^b   Dhalla, Naranjan S ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b All India of Medical Sciences ^*  (India)

Author keywords

c jun N terminal protein kinases; Cardiac hypertrophy; Extracellular signal regulated kinases; Heart failure; Mitogen activated protein kinase; p38 kinases

Indexed keywords

GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHORBOL ESTER; PHOSPHATASE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR;

APOPTOSIS; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CYTOPLASM; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE ISCHEMIA; HUMAN; INTRACELLULAR TRANSPORT; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RAT; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

EID: 3142770716     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (166)

1. Schluter KD, Piper HM. Regulation of growth in the adult cardiomyocytes. FASEB J 1999;13(Suppl):S17-22.
2. Ma XL, Kumar S, Gao F, et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 1999;99:1685-91.
3. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994;94:1621-8.
4. Roulston A, Reinhard C, Amiri P, Williams LT. Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor alpha. J Biol Chem 1998;273:10232-9.
5. Bogoyevitch MA, Andersson MB, Gillespie-Brown J, et al. Adrenergic receptor stimulation of the mitogen-activated protein kinase cascade and cardiac hypertrophy. Biochem J 1996;314:115-21.
6. Yamauchi-Takihara K, Hirota H, Kunisada K, et al. Roles of gp130 signaling pathways in cardiac myocytes: Recent advances and implications for cardiovascular disease. J Card Fail 1996;2(Suppl):S63-8.
7. Pellieux C, Sauthier T, Aubert JF, Brunner HR, Pedrazzini T. Angiotensin II-induced cardiac hypertrophy is associated with different mitogen-activated protein kinase activation in normotensive and hypertensive mice. J Hypertens 2000;18:1307-17.
8. Aoki H, Richmond M, Izumo S, Sadoshima J. Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro. Biochem J 2000;347:275-84.
9. Tsutsumi Y, Matsubara H, Ohkubo N, et al. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res 1998;83:1035-46.
10. Clerk A, Sugden PH. Activation of protein kinase cascades in the heart by hypertrophic G protein-coupled receptor agonists. Am J Cardiol 1999;83:64H-9H.
11. Katz AM. Maladaptive hypertrophy and the cardiomyopathy of overload: Familial cardiomyopathies. In: Heart Failure Pathophysiology, Molecular Biology, and Clinical Management. Philadelphia: Lippincott Williams & Wilkins, 2000:277-307.
12. Dhalla NS, Afzal N, Beamish RE, Naimark B, Takeda N, Nagano M. Pathophysiology of cardiac dysfunction in congestive heart failure. Can J Cardiol 1993;9:873-87.
13. Wang Y. Signal transduction in cardiac hypertrophy - dissecting compensatory versus pathological pathways utilizing a transgenic approach. Curr Opin Pharmacol 2001;1:134-40.
14. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46.
15. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107-15.
16. Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J 1999;20:136-9.
17. Izumo S, Lompre AM, Matsuoka R, et al. Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals. J Clin Invest 1987;79:970-7.
18. Komuro I, Kurabayashi M, Takaku F, Yazaki Y. Expression of cellular oncogenes in the myocardium during the developmental stage and pressure-overloaded hypertrophy of the rat heart. Circ Res 1988;62:1075-9.
19. Mulvagh SL, Michael LH, Perryman MB, Roberts R, Schneider MD. A hemodynamic load in vivo induces cardiac expression of the cellular oncogene, c-myc. Biochem Biophys Res Commun 1987;147:627-36.
20. Starksen NF, Simpson PC, Bishopric N, et al. Cardiac myocyte hypertrophy is associated with c-myc protooncogene expression. Proc Natl Acad Sci USA 1986;83:8348-50.
21. Izumo S, Nadal-Ginard B, Mahdavi V. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci USA 1988;85:339-43.
22. Brand T, Sharma HS, Fleischmann KE, et al. Proto-oncogene expression in porcine myocardium subjected to ischemia and reperfusion. Circ Res 1992;71:1351-60.
23. Knoll R, Arras M, Zimmermann R, Schaper J, Schaper W. Changes in gene expression following short coronary occlusions studied in porcine hearts with run-on assays. Cardiovasc Res 1994;28:1062-9.
24. Komuro I, Yazaki Y. Control of cardiac gene expression by mechanical stress. Annu Rev Physiol 1993;55:55-75.
25. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 1997;59:551-71.
26. Yamazaki T, Komuro I, Yazaki Y. Molecular mechanism of cardiac cellular hypertrophy by mechanical stress. J Mol Cell Cardiol 1995;27:133-40.
27. Miner JH, Wold BJ. c-myc inhibition of MyoD and myogenin-initiated myogenic differentiation. Mol Cell Biol 1991;11:2842-51.
28. Lanahan A, Williams JB, Sanders LK, Nathans D. Growth factor-induced delayed early response genes. Mol Cell Biol 1992;12:3919-29.
29. Vincent S, Marty L, Le Gallic L, Jeanteur P, Fort P. Characterization of late response genes sequentially expressed during renewed growth of fibroblastic cells. Oncogene 1993;8:1603-10.
30. Katz AM. Signal transduction within cells of the failing heart. In: Heart Failure Pathophysiology, Molecular Biology, and Clinical Management. Philadelphia: Lippincott Williams & Wilkins, 2000:237-76.
31. Livingstone C, Patel G, Jones N. ATF-2 contains a phosphorylation-dependent transcriptional activation domain. EMBO J 1995;14:1785-97.
32. Katz AM. The hypertrophic response: Programmed cell death. In: Heart Failure Pathophysiology, Molecular Biology, and Clinical Management. Philadelphia: Lippincott Williams & Wilkins, 2000:173-226.
33. Bishopric NH, Andreka P, Slepak T, Webster KA. Molecular mechanisms of apoptosis in the cardiac myocyte. Curr Opin Pharmacol 2001;1:141-50.
34. Guerra S, Leri A, Wang X, et al. Myocyte death in the failing human heart is gender dependent. Circ Res 1999;85:856-66.
35. Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: Implications for human obesity. Proc Natl Acad Sci USA 2000;97:1784-9.
36. Freude B, Masters TN, Robicsek F, et al. Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J Mol Cell Cardiol 2000;32:197-208.
37. Sam F, Sawyer DB, Chang DL, et al. Progressive left ventricular remodeling and apoptosis late after myocardial infarction in mouse heart. Am J Physiol Heart Circ Physiol 2000;279:H422-8.
38. Tea BS, Dam TV, Moreau P, Hamet P, deBlois D. Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity. Hypertension 1999;34:229-35.
39. Hirota H, Chen J, Betz UA, et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 1999;97:189-98.
40. Buja LM, Entman ML. Modes of myocardial cell injury and cell death in ischemic heart disease. Circulation 1998;98:1355-7.
41. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995;377:744-7.
42. Malarkey K, Belham CM, Paul A, et al. The regulation of tyrosine kinase signalling pathways by growth factor and G-protein-coupled receptors. Biochem J 1995;309:361-75.
43. Chesley A, Lundberg MS, Asai T, et al. The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3′-kinase. Circ Res 2000;87:1172-9.
44. Hibi M, Lin A, Smeal T, Minden A, Karin M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 1993;7:2135-48.
45. Cano E, Hazzalin CA, Mahadevan LC. Anisomycin-activated protein kinases p45 and p55 but not mitogen-activated protein kinases ERK-1 and -2 are implicated in the induction of c-fos and c-jun. Mol Cell Biol 1994;14:7352-62.
46. Gille H, Sharrocks AD, Shaw PE. Phosphorylation of transcription factor p62TCF by MAP kinase stimulates ternary complex formation at c-fos promoter. Nature 1992;358:414-7.
47. Aikawa R, Komuro I, Yamazaki T, et al. Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes. Circ Res 1999;84:458-66.
48. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985;57:84-95.
49. Sturgill TW, Wu J. Recent progress in characterization of protein kinase cascades for phosphorylation of ribosomal protein S6. Biochim Biophys Acta 1991;1092:350-7.
50. Laderoute KR, Webster KA. Hypoxia/reoxygenation stimulates Jun kinase activity through redox signaling in cardiac myocytes. Circ Res 1997;80:336-44.
51. Sadoshima J, Qiu Z, Morgan JP, Izumo S. Angiotensin II and other hypertrophic stimuli mediated by G protein-coupled receptors activate tyrosine kinase, mitogen-activated protein kinase, and 90-kD S6 kinase in cardiac myocytes. The critical role of Ca(2+)-dependent signaling. Circ Res 1995;76:1-15.
52. Cook S, McCormick F. Ras blooms on sterile ground. Nature 1994;369:361-2.
53. Dostal DE, Hunt RA, Kule CE, et al. Molecular mechanisms of angiotensin II in modulating cardiac function: Intracardiac effects and signal transduction pathways. J Mol Cell Cardiol 1997;29:2893-902.
54. Crespo P, Xu N, Simonds WF, Gutkind JS. Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits. Nature 1994;369:418-20.
55. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997;390:88-91.
56. Sakata Y, Hoit BD, Liggett SB, Walsh RA, Dorn GW. Decompensation of pressure-overload hypertrophy in G alpha q-overexpressing mice. Circulation 1998;97:1488-95.
57. Taylor SJ, Chae HZ, Rhee SG, Exton JH. Activation of the beta 1 isozyme of phospholipase C by alpha subunits of the Gq class of G proteins. Nature 1991;350:516-8.
58. Hefti MA, Harder BA, Eppenberger HM, Schaub MC. Signaling pathways in cardiac myocyte hypertrophy. J Mol Cell Cardiol 1997;29:2873-92.
59. Luttrell LM, van Biesen T, Hawes BE, et al. G-protein-coupled receptors and their regulation: Activation of the MAP kinase signaling pathway by G-protein-coupled receptors. Adv Second Messenger Phosphoprotein Res 1997;31:263-77.
60. Pelech SL, Charest DL. MAP kinase-dependent pathways in cell cycle control. Prog Cell Cycle Res 1995;1:33-52.
61. Steinberg SF, Goldberg M, Rybin VO. Protein kinase C isoform diversity in the heart. J Mol Cell Cardiol 1995;27:141-53.
62. Farnsworth CL, Freshney NW, Rosen LB, Ghosh A, Greenberg ME, Feig LA. Calcium activation of Ras mediated by neuronal exchange factor Ras-GRF. Nature 1995;376:524-7.
63. Komuro I, Yazaki Y. Intracellular signaling pathways in cardiac myocytes induced by mechanical stress. Trends Cardiovasc Med 1994;4:117-21.
64. Cook SJ, McCormick F. Inhibition by cAMP of Ras-dependent activation of Raf. Science 1993;262:1069-72.
65. Liu M, Simon MI. Regulation by cAMP-dependent protein kinease of a G-protein-mediated phospholipase C. Nature 1996;382:83-7.
66. Sevetson BR, Kong X, Lawrence JC Jr. Increasing cAMP attenuates activation of mitogen-activated protein kinase. Proc Natl Acad Sci USA 1993;90:10305-9.
67. Yamazaki T, Komuro I, Zou Y, et al. Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both alpha 1- and beta-adrenoceptors. Circulation 1997;95:1260-8.
68. Gonzalez FA, Seth A, Raden DL, Bowman DS, Fay FS, Davis RJ. Serum-induced translocation of mitogen-activated protein kinase to the cell surface ruffling membrane and the nucleus. J Cell Biol 1993;122:1089-101.
69. Gille H, Kortenjann M, Thomae O, et al. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J 1995; 14:951-62.
70. Marais R, Wynne J, Treisman R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 1993;73:381-93.
71. Treisman R. Ternary complex factors: Growth factor regulated transcriptional activators. Curr Opin Genet Dev 1994;4:96-101.
72. Sprenkle AB, Murray SF, Glembotski CC. Involvement of multiple cis elements in basal- and alpha-adrenergic agonist-inducible atrial natriuretic factor transcription. Roles for serum response elements and an SP-1-like element. Circ Res 1995;77:1060-9.
73. Ward Y, Gupta S, Jensen P, Wartmann M, Davis RJ, Kelly K. Control of MAP kinase activation by the mitogen-induced threonine/tyrosine phosphatase PAC1. Nature 1994;367:651-4.
74. Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ. Integration of MAP kinase signal transduction pathways at the serum response element. Science 1995;269:403-7.
75. van Dam H, Wilhelm D, Herr I, Steffen A, Herrlich P, Angel P. ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J 1995;14:1798-811.
76. Cook SA, Sugden PH, Clerk A. Activation of c-jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease. J Mol Cell Cardiol 1999;31:1429-34.
77. Vojtek AB, Der CJ. Increasing complexity of the Ras signaling pathway. J Biol Chem 1998;273:19925-8.
78. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001;81:153-208.
79. Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994;265:808-11.
80. Bird TA, Kyriakis JM, Tyshler L, Gayle M, Milne A, Virca GD. Interleukin-1 activates p54 mitogen-activated protein (MAP) kinase/stress-activated protein kinase by a pathway that is independent of p21ras, Raf-1, and MAP kinase kinase. J Biol Chem 1994;269:31836-44.
81. LaPointe MC, Isenovic E. Interteukin-1beta regulation of inducible nitric oxide synthase and cyclooxygenase-2 involves the p42/44 and p38 MAPK signaling pathways in cardiac myocytes. Hypertension 1999;33:276-82.
82. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-52.
83. Minamino T, Yujiri T, Papst PJ, Chan ED, Johnson GL, Terada N. MEKK1 suppresses oxidative stress-induced apoptosis of embryonic stem cell-derived cardiac myocytes. Proc Natl Acad Sci USA 1999;96:15127-32.
84. Kang YJ, Zhou ZX, Wang GW, Buridi A, Klein J.B. Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J Biol Chem 2000;275:13690-8.
85. De Windt LJ, Lim HW, Taigen T, et al. Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure. Circ Res 2000;86:255-63.
86. Andreka P, Zang J, Dougherty C, Slepak TI, Webster KA, Bishopric NH. Cytoprotection by Jun kinase during nitric oxide-induced cardiac myocyte apoptosis. Circ Res 2001;88:305-12.
87. Zou Y, Komuro I, Yamazaki T, et al. Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes. J Biol Chem 1996;271:33592-7.
88. Pfeffer JM, Fischer TA, Pfeffer MA. Angiotensin-converting enzyme inhibition and ventricular remodeling after myocardial infarction. Annu Rev Physiol 1995;57:805-26.
89. Ichiki T, Labosky PA, Shiota C, et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995;377:748-50.
90. Shao Q, Panagia V, Beamish RE, Dhalla NS. Role of renin-angiotensin system in cardiac hypertrophy and failure. In: Dhalla NS, Zahradka P, Dixon IMC, Beamish RE, eds. Angiotensin II Receptor Blockade: Physiological and Clinical Implications. Boston: Kluwer Academic Publishers, 1998:283-310.
91. Ho PD, Zechner DK, He H, Dillman WH, Glembotski CC, McDonough PM. The Raf-MEK-ERK cascade represents a common pathway for alteration of intracellular calcium by Ras and protein kinase C in cardiac myocytes. J Biol Chem 1998;273:21730-5.
92. Schluter KD, Simm A, Schafer M, Taimor G, Piper HM. Early response kinase and PI 3-kinase activation in adult cardiomyocytes and their role in hypertrophy. Am J Physiol 1999;276:H1655-63.
93. Stefanovsky VY, Pelletier G, Hannan R, Gagnon-Kugler T, Rothblum LI, Moss T. An immediate response of ribosomal transcription to growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF. Mol Cell 2001;8:1063-73.
94. Liang Q, Wiese R, Bueno O, Dai Y, Markham B, Molkentin J. The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol Cell Biol 2001;21:7460-9.
95. Takeishi Y, Bhagwat A, Ball NA, Kirkpatrick DL, Periasamy M, Walsh RA. Effect of angiotensin-converting enzyme inhibition on protein kinase C and SR proteins in heart failure. Am J Physiol 1999;276:H53-62.
96. Hefti MA, Harder BA, Eppenberger HM, Schaub MC. Signaling pathways in cardiac myocyte hypertrophy. J Mol Cell Cardiol 1997;29:2873-92.
97. Shao Q, Takeda N, Temsah R, Dhalla KS, Dhalla NS. Prevention of hemodynamic changes due to myocardial infarction by early treatment of rats with imidapril. Cardiovasc Pathobiol 1996;1:180-6.
98. Weinberg ED, Schoen FJ, George D, et al. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 1994;90:1410-22.
99. Lazou A, Sugden PH, Clerk A. Activation of mitogen-activated protein kinases (p38-MAPKs, SAPKs/JNKs and ERKs) by the G-protein-coupled receptor agonist phenylephrine in the perfused rat heart. Biochem J 1998;332:459-65.
100. Haq S, Choukroun G, Lim H, et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 2001;103:670-7.
101. Yano M, Kim S, Izumi Y, Yamanaka S, Iwao H. Differential activation of cardiac c-jun amino-terminal kinase and extracellular signal-regulated kinase in angiotensin II-mediated hypertension. Circ Res 1998;83:752-60.
102. Yamazaki T, Komuro I, Shiojima I, Yazaki Y. Angiotensin II mediates mechanical stress-induced cardiac hypertrophy. Diabetes Res Clin Pract 1996;30(Suppl):107-11.
103. Harada K, Komuro I, Zou Y, et al. Acute pressure overload could induce hypertrophic responses in the heart of angiotensin II type 1a knockout mice. Circ Res 1998;82:779-85.
104. Izumi Y, Kim S, Murakami T, Yamanaka S, Iwao H. Cardiac mitogen-activated protein kinase activities are chronically increased in stroke-prone hypertensive rats. Hypertension 1998;31:50-6.
105. Komuro I, Kudo S, Yamazaki T, Zou Y, Shiojima J, Yazaki Y. Mechanical stretch activates the stress-activated protein kinases in cardiac myocytes. FASEB J 1996; 10:631-6.
106. Takemoto Y, Yoshiyama M, Takeuchi K, et al. Increased JNK, AP-1 and NF-kappa B DNA binding activities in isoproterenol-induced cardiac remodeling. J Mol Cell Cardiol 1999;31:2017-30.
107. Yoshida K, Yoshiyama M, Omura T, et al. Activation of mitogen-activated protein kinases in the non-ischemic myocardium of an acute myocardial infarction in rats. Jpn Circ J 2001;65:808-14.
108. Behrends M, Schulz R, Post H, et al. Inconsistent relation of MAPK activation to infarct size reduction by ischemic preconditioning in pigs. Am J Physiol Heart Circ Physiol 2000;279:H1111-9.
109. Talmor D, Applebaum A, Rudich A, Shapira Y, Tirosh A. Activation of mitogen-activated protein kinases in heart during cardiopulmonary bypass. Circ Res 2000;86:1004-7.
110. Yue T, Gu J, Wang C, et al. Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J Biol Chem 2000;275:37895-901.
111. Araujo E, Bianchi C, Faro R, Sellke F. Oscillation in the activities of MEK/ERK1/2 during cardiopulmonary bypass in pigs. Surgery 2001;130:182-91.
112. Takeishi Y, Huang Q, Wang T, et al. Src family kinase and adenosine differentially regulate multiple MAP kinases in ischemic myocardium: Modulation of MAP kinases activation by ischemic preconditioning. J Mol Cell Cardiol 2001;33:1989-2005.
113. Knight R, Buxton D. Stimulation of c-Jun kinase and mitogen-activated protein kinase by ischemia and reperfusion in the perfused rat heart. Biochem Biophys Res Commun 1996;218:83-8.
114. Bogoyevitch MA, Sugden PH. The role of protein kinases in adaptational growth of the heart. Int J Biochem Cell Biol 1996;28:1-12.
115. Bogoyevitch MA, Glennon PE, Andersson MB, et al. Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes. The potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy. J Biol Chem 1994;269:1110-9.
116. Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ, et al. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ Res 1996;79:162-73.
117. Yue TL, Wang C, Guo JL, et al. Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res 2000;86:692-9.
118. Communal C, Colucci WS, Singh K. p38 mitogen-activated protein kinase pathway protects adult rat ventricular myocytes against beta-adrenergic receptor-stimulated apoptosis. Evidence for Gi-dependent activation. J Biol Chem 2000;275:19395-400.
119. Bueno OF, De Windt LJ, Tymitz KM, et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 2000;19:6341-50.
120. Araki M, Hasegawa K, Iwai-Kanai E, et al. Endothelin-1 as a protective factor against beta-adrenergic agonist-induced apoptosis in cardiac myocytes. J Am Coll Cardiol 2000;36:1411-8.
121. Iwai-Kanai E, Hasegawa K, Araki M, Kakita T, Morimoto T, Sasayama S. Alpha- and beta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. Circulation 1999;100:305-11.
122. Sugden PH. Signaling in myocardial hypertrophy: Life after calcineurin? Circ Res 1999;84:633-46.
123. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999;33:613-21.
124. Kyriakis JM, Brautigan DL, Ingebritsen TS, Avruch J. pp54 microtubule-associated protein-2 kinase requires both tyrosine and serine/threonine phosphorylation for activity. J Biol Chem 1991;266:10043-6.
125. Davis RJ. Transcriptional regulation by MAP kinases. Mol Reprod Dev 1995;42:459-67.
126. Gupta S, Campbell D, Derijard B, Davis RJ. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995;267:389-93.
127. Kyriakis JM, Banerjee P, Nikolakaki E, et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 1994;369:156-60.
128. Sluss HK, Barrett T, Derijard B, Davis RJ. Signal transduction by tumor necrosis factor mediated by JNK protein kinases. Mol Cell Biol 1994;14:8376-84.
129. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-31.
130. Wang Y, Su B, Shah VP, Brown JH, Han J, Chien KR. Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. J Biol Chem 1998;273:5423-6.
131. Wang Y, Huang S, Shah VP, et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 1998;273:2161-8.
132. Bueno OF, De Windt LJ, Lim HW, et al. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ Res 2001;88:88-96.
133. Clerk A, Michael A, Sugden PH. Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein-coupled receptor agonists, endothelin-1 and phenylephrine: A role in cardiac myocyte hypertrophy? J Cell Biol 1998;142:523-35.
134. Bogoyevitch MA, Ketterman AJ, Sugden PH. Cellular stresses differentially activate c-Jun N-terminal protein kinases and extracellular signal-regulated protein kinases in cultured ventricular myocytes. J Biol Chem 1995;270:29710-7.
135. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-31.
136. Tournier C, Hess P, Yang DD, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000;288:870-4.
137. Andreka P, Zang J, Dougherty C, Slepak TI, Webster KA, Bishopric NH. Cytoprotection by Jun kinase during nitric oxide-induced cardiac myocyte apoptosis. Circ Res 2001;88:305-12.
138. Sato M, Cordis GA, Maulik N, Das DK. SAPKs regulation of ischemic preconditioning. Am J Physiol Heart Circ Physiol 2000;279:H901-7.
139. Sanada S, Kitakaze M, Papst PJ, et al. Role of phasic dynamism of p38 mitogen-activated protein kinase activation in ischemic preconditioning of the canine heart. Circ Res 2001;88:175-80.
140. Tekin D, Xi L, Zhao T, Tejero-Taldo MI, Atluri S, Kukreja RC. Mitogen-activated protein kinases mediate heat shock-induced delayed protection in mouse heart. Am J Physiol Heart Circ Physiol 2001;281:H523-32.
141. Kunapuli P, Lawson JA, Rokach JA, Meinkoth JL, FitzGerald GA. Prostaglandin F2alpha (PGF2alpha) and the isoprostane, 8, 12-iso-isoprostane F2alpha-III, induce cardiomyocyte hypertrophy. Differential activation of downstream signaling pathways. J Biol Chem 1998;273:22442-52.
142. Qin F, Shite J, Liang CS. Antioxidants attenuate myocyte apoptosis and improve cardiac function in CHF: Association with changes in MAPK patways. Am J Physiol Heart Circ Physiol 2003;285:H822-32.
143. Rabkin SW, Sunga PS, Sanghera JS, Pelech SL. Reduction of angiotensin II-induced activation of mitogen-activated protein kinase in cardiac hypertrophy. Cell Mol Life Sci 1997;53:951-9.
144. Rouse J, Cohen P, Trigon S, et al. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 1994;78:1027-37.
145. Sugden PH, Clerk A. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res 1998;83:345-52.
146. Zhang S, Han J, Sells M, et al. Rho family GTP-ases regulate p38 mitogen-activated protein kinase through the downstream mediator PAK1. J Biol Chem 1995;270:23934-6.
147. Tibbles L, Ing Y, Kiefer F, et al. MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6. EMBO J 1996;15:7026-35.
148. Fan G, Merrit S, Kortenjann M, Shaw P, Holzman L. Dual leucine zipper-bearing kinase (DLK) activates p46SAPK and p38 MAPK but not ERK2. J Biol Chem 1996;271:24788-93.
149. Raingeaud J, Gupta S, Rogers JS, et al. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995;270:7420-6.
150. Zhu W, Zou Y, Aikawa R, et al. MAPK superfamily plays an important role in daunomycin-induced apoptosis of cardiac myocytes. Circulation 1999;100:2100-7.
151. Mackay K, Mochly-Rosen D. Involvement of a p38 mitogen-activated protein kinase phosphatase in protecting neonatal rat cardiac myocytes from ischemia. J Mol Cell Cardiol 2000;32:1585-8.
152. Schneider S, Chen W, Hou J, Steenbergen C, Murphy E. Inhibition of p38 MAPK alpha/beta reduces ischemic injury and does not block protective effects of preconditioning. Am J Physiol Heart Circ Physiol 2001;280:H499-508.
153. Barancik M, Htun F, Strohm C, Kilian S, Schaper W. Inhibition of the cardiac p38-MAPK pathway by SB203580 delays ischemic cell death. J Cardiovasc Pharmacol 2000;35:474-83.
154. Cain B, Meldrum D, Meng X, et al. p38 MAPK inhibition decreases TNF-alpha production and enhances postischemic human myocardial function. J Surg Res 1999;83:7-12.
155. Nakano A, Cohen M, Critz S, Downey J. SB 203580, an inhibitor of p38 MAPK, abolishes infarct-limiting effects of ischemic preconditioning in isolated rabbit hearts. Basic Res Cardiol 2000;95:466-71.
156. Craig R, Larkin A, Mingo AM, et al. p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. J Biol Chem 2000;275:23814-24.
157. Hoover HE, Thuerauf DJ, Martindale JJ, Glembotski CC. Alpha B-crystallin gene induction and phosphorylation by MKK6-activated p38. A potential role for alpha B-crystallin as a target of the p38 branch of the cardiac stress response. J Biol Chem 2000;275:23825-33.
158. Ueyama T Kawashima S, Sakoda T, et al. Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy. J Mol Cell Cardiol 2000;32:947-60.
159. De Windt LJ, Lim HW, Haq S, Force T, Molkentin JD. Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways. J Biol Chem 2000;275:13571-9.
160. Liang F, Lu S, Gardner DG. Endothelin-dependent and -independent components of strain-activated brain natriuretic peptide gene transcription require extracellular signal regulated kinase and p38 mitogen-activated protein kinase. Hypertension 2000;35:188-92.
161. Silberbach M, Gorenc T, Hershberger RE, Stork PJ, Steyger PS, Roberts CT. Extracellular signal-regulated protein kinase activation is required for the anti-hypertrophic effect of atrial natriuretic factor in neonatal rat ventricular myocytes. J Biol Chem 1999;274:24858-64.
162. Nemoto S, Sheng Z, Lin A. Opposing effects of Jun kinase and p38 mitogen-activated protein kinases on cardiomyocyte hypertrophy. Mol Cell Biol 1998;18:3518-26.
163. Choukroun G, Hajjar R, Fry S, et al. Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases. J Clin Invest 1999;104:391-8.
164. Kudoh S, Komuro I, Hiroi Y, et al. Mechanical stretch induces hypertrophic responses in cardiac myocytes of angiotensin II type 1a receptor knockout mice. J Biol Chem 1998;273:24037-43.
165. Wang M, Wang T, Liu L. Expression of mitogen-activated protein kinase in hypertrophic myocardium in SHRsp. Zhonghua Yi Xue Za Zhi 1997;77:680-2.
166. Li WG, Zaheer A, Coppey L, Oskarsson HJ. Activation of JNK in the remote myocardium after large myocardial infarction in rats. Biochem Biophys Res Common 1998;246:816-20.